Zennova Pharmaceuticals recently announced significant advancements in its innovative leukemia drug, Zenno-10, based on its proprietary single-nano drug delivery platform, BioCarier^®. The latest human clinical trials have demonstrated notable improvements in the drug's bioavailability, significantly reducing the impact of food intake on drug absorption. Additionally, the toxicity and side effects associated with Zenno-10 have been substantially minimized. These crucial clinical findings establish a strong foundation for Zenno-10's global marketing and its future launch in both China and the United States. This also reaffirms the advanced technological progress of the BioCarier^® platform in enhancing the drug delivery of BCS-IV low solubility and low permeability drug molecules, as well as peptide drugs. 

The clinical trial employed a single-center, single oral administration, randomized, open-label design over three cycles within a 31-day period. All participants successfully completed the entire clinical process without experiencing any significant side effects. This discovery paves the way for the BioCarier^® platform to be utilized in human clinical applications.

Zenno-10 is developed by Zennova Pharmaceuticals utilizing BioCarier^® technology. It serves as an innovative first-line therapy for lymphoma, targeting adult chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as newly diagnosed adult acute myeloid leukemia (AML). Zenno-10 is classified as a low solubility, low permeability (BCS-IV) molecule, with an existing oral tablet form having only 5% bioavailability, which is significantly affected by food and other medications.

Thanks to BioCarier^® technology, Zenno-10 has achieved remarkable breakthroughs in several areas:

- Significantly improved bioavailability**: When taken in a fasting state, BioCarier^® technology increases Zenno-10's bioavailability to 500% compared to similar products on the market.

- Elimination of food interference**: Traditional drug absorption can fluctuate by up to 400% due to food intake, whereas the absorption of Zenno-10 remains unaffected by food, significantly enhancing medication safety and efficacy stability.

- Reduced side effects**: BioCarier™ technology enhances drug absorption efficiency, allowing for an 80% lower dosage of Zenno-10 compared to similar products, which greatly reduces the toxic side effects associated with higher dosages.

Currently, Zennova Pharmaceuticals is advancing Zenno-10 into new clinical research areas, exploring its potential to overcome drug interference and cross the blood-brain barrier. The company also aims to further develop the BioCarier^® technology platform, with a focus on BCS-IV and peptide molecular drugs, and is committed to advancing the development of additional new drugs.

While enhancing its independent research and development efforts, Zennova Pharmaceuticals has initiated outward-looking technical collaborations on the BioCarier^® platform, seeking partnerships to jointly promote the widespread application of its single-nano drug delivery technology.